Vicriviroc

• Description :

  Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM, , respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer[1][2].

• Product Name Alternative :

  SCH 417690; SCH-D; MK-7690 (free base)

• UNSPSC :

  12352005

• Target :

  CCR; HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection

• Assay Protocol :

  https://www.medchemexpress.com/vicriviroc.html

• Smiles :

  COC[C@@H](C1=CC=C(C=C1)C(F)(F)F)N2[C@H](CN(C3(CCN(CC3)C(C4=C(C)N=CN=C4C)=O)C)CC2)C

• Molecular Formula :

  C28H38F3N5O2

• Molecular Weight :

  533.63

• References & Citations :

  [1]Strizki JM, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49 (12) :4911-4919. |[2]Bessudo A, et al. Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clin Colorectal Cancer. 2024;23 (3) :285-294.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [306296-47-9]